Monofer Cuts Frequency, Cost of Iron Infusions for Danish IDA Patients, Study Says

Monofer Cuts Frequency, Cost of Iron Infusions for Danish IDA Patients, Study Says
Use of Monofer (iron isomaltoside) instead of Ferinject (ferric carboxymaltose, also known as Injectafer in the U.S.) reduces the number of iron infusions required by people with inflammatory bowel disease (IBD) and associated iron deficiency anemia (IDA), a Danish nationwide study revealed. The reduced need for iron infusions was found to promote significant cost savings compared to use of Ferinject, researchers reported. The study, “An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark,” was published in the journal Advances in Therapy. IDA is a common complication of IBD, caused by persistent blood loss through the intestines and impaired absorption of nutrients such as iron and vitamin B12. To manage this and prevent its worsening, iron infusions are often the first treatment in patients with active IBD who are intolerant to oral iron or have reduced hemoglobin (the protein that transports oxygen in the blood) levels. “Intravenous iron is more effective, shows a faster response and is better tolerated than oral iron in these patients,” researchers said. The incidence of IBD has increased over the past few decades, particularly in Denmark, among the countries with the highest incidence of the disease in the world. G
Subscribe or to access all post and page content.